Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Al-Dawaa Medical Services Company (4163.SR)
Al Khobar, Eastern Province, SA
Al-Dawaa Medical Services Company operates as a prominent pharmaceutical retail enterprise throughout the Kingdom of Saudi Arabia, conducting its business through distinct retail and wholesale divisions. The company provides a comprehensive selection of products, including pharmaceuticals, fragrances, beauty accessories, cosmetics, and other general healthcare items. Beyond its core sales operations, Al-Dawaa is actively involved in managing pharmacies, overseeing pharmaceutical warehouses, retailing medical equipment, offering land transportation for goods, managing self-storage facilities, and providing marketing services for external entities. It also serves as a pharmaceutical agent. The company connects with customers via an extensive network of 837 pharmacies, augmented by its online and wholesale distribution channels. Al-Dawaa Medical Services Company was established in 1991 and is based in Al Khobar, Saudi Arabia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.99% | -5.83% | -12.66% | -11.77% | -21.38% | -13.19% | -45.58% | -54.59% | -44.89% | -44.89% | -44.89% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 6 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+4.4% Q1'26: -6.4% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%-12.9% Q1'26: -79.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+6.2% Q1'26: +8.8% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+6.9% ★ Q1'26: +3.6% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+12.3% ★
-
Share dilution Medical - Pharmaceuticals: +0.0%-0.1% ★ Q1'26: +0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×2.60× Q1'26: 10.29× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 4 EPS Ana. |
Dec 2027 5 Rev. Ana. 4 EPS Ana. |
Dec 2028 1 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
Dec 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.03B
est: 5.17B (-2.6%)
|
5.37B
est: 5.26B (+2.2%)
|
5.74B
est: 6.00B (-4.3%)
|
6.45B
est: 6.30B (+2.4%)
|
6.74B
est: 6.80B (-0.9%)
|
6.78B
6.58B – 7.02B
-0.3% YoY
|
7.12B
6.97B – 7.38B
+5.0% YoY
|
7.51B
7.32B – 7.78B
+5.5% YoY
|
7.98B
7.78B – 8.27B
+6.3% YoY
|
7.87B
7.67B – 8.16B
-1.4% YoY
|
| EBITDA |
662.66M
est: 710.81M (-6.8%)
|
784.25M
est: 723.15M (+8.4%)
|
830.43M
est: 830.37M (+0.0%)
|
896.73M
est: 871.69M (+2.9%)
|
880.78M
est: 940.98M (-6.4%)
|
938.08M
910.08M – 972.26M
-0.3% YoY
|
985.14M
964.09M – 1.02B
+5.0% YoY
|
1.04B
1.01B – 1.08B
+5.5% YoY
|
1.11B
1.08B – 1.15B
+6.3% YoY
|
1.09B
1.06B – 1.13B
-1.4% YoY
|
| EBIT |
328.79M
est: 382.87M (-14.1%)
|
434.88M
est: 389.52M (+11.6%)
|
466.69M
est: 433.88M (+7.6%)
|
514.08M
est: 455.46M (+12.9%)
|
464.09M
est: 491.67M (-5.6%)
|
490.15M
475.52M – 508.01M
-0.3% YoY
|
514.74M
503.74M – 533.34M
+5.0% YoY
|
542.96M
529.12M – 562.67M
+5.5% YoY
|
577.37M
562.64M – 598.32M
+6.3% YoY
|
569.46M
554.93M – 590.12M
-1.4% YoY
|
| Net Income |
239.14M
est: 268.60M (-11.0%)
|
305.45M
est: 252.55M (+20.9%)
|
329.22M
est: 354.84M (-7.2%)
|
370.11M
est: 370.64M (-0.1%)
|
321.76M
est: 357.78M (-10.1%)
|
287.33M
251.53M – 323.14M
-19.7% YoY
|
292.61M
229.85M – 355.36M
+1.8% YoY
|
316.41M
305.92M – 331.34M
+8.1% YoY
|
374.39M
361.98M – 392.05M
+18.3% YoY
|
384.58M
371.83M – 402.72M
+2.7% YoY
|
| SGA |
259.24M
est: 435.15M (-40.4%)
|
263.97M
est: 442.71M (-40.4%)
|
246.98M
est: 221.26M (+11.6%)
|
262.82M
est: 232.26M (+13.2%)
|
—
est: 250.73M (-100.0%)
|
249.95M
242.49M – 259.06M
-0.3% YoY
|
262.49M
256.88M – 271.98M
+5.0% YoY
|
276.88M
269.82M – 286.93M
+5.5% YoY
|
294.43M
286.92M – 305.11M
+6.3% YoY
|
290.39M
282.99M – 300.93M
-1.4% YoY
|
| EPS |
2.81
est: 3.16 (-11.1%)
|
3.59
est: 2.97 (+20.8%)
|
3.87
est: 4.17 (-7.3%)
|
4.35
est: 4.24 (+2.7%)
|
3.79
est: 4.20 (-9.8%)
|
3.38
2.96 – 3.81
-19.5% YoY
|
3.49
2.71 – 4.19
+3.0% YoY
|
3.73
3.60 – 3.90
+6.9% YoY
|
4.41
4.26 – 4.62
+18.3% YoY
|
4.53
4.38 – 4.74
+2.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-09 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-06-08 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-06-07 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-06-04 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-06-03 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-06-02 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-06-01 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-31 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-17 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-10 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-26 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-19 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Saudi Arabia ETF KSA | 0.14% | 880.0K | 0.75% |
| 2 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.02% | 87.2K | 0.72% |
| 3 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.02% | 68.4K | 0.74% |
| 4 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.01% | 16.3K | 0.42% |
| 5 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.01% | 76.7K | 0.55% |
| 6 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 29.3K | 0.56% |
| 7 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.23M | 0.06% |
| 8 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.01% | 647.9K | 0.39% |
| 9 | Avantis Emerging Markets Value ETF AVES | 0.01% | 93.5K | 0.36% |
| 10 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 322.7K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ahmed Ali Abdul Al-Mowafi | Head of the Operation Department | — | — |
| Fahad Abdullah Saad Al-Faraj | Head of Strategy & Organizational Performance Department | — | — |
| Mahmoud Marzouk Taha Hassan | Secretary of the Board of Directors | — | — |
| Mohammed Saad Butti Al-Farraj Al-Subaie | Chief Executive Officer & Executive Director | — | male |
| Muhammad Fathi El-Sherbiny Ali | Head of Legal Department | — | — |
| Saud Zaid Faleh Al-Arini | Head of Human Resources & Administration Department | — | — |
| Shareef Ahmed Al-Aqabawi | Chief Financial Officer | — | male |
| Turki Abdullah Saad Al-Farraj | Head of Marketing Department | — | — |
| Vigay Sigar | Head of Business Development Department | — | — |
| Waleed Bin Mohammad Bin Abdullah Al-Jafaari | MD & Executive Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4163.SR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
